×
About 412,224 results
Screening for Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: U...
https://doi.org/10.1001/jama.2018.14741
JAMA , Curry SJ et. al.

Oct 25th, 2018 - Intimate partner violence (IPV) and abuse of older or vulnerable adults are common in the United States but often remain undetected. In addition to the immediate effects of IPV, such as injury and death, there are other health consequences, many with long-term effects, including development of mental health conditions such as depression, posttraumatic stress disorder, anxiety disorders, substan...

ACOG Committee Opinion No. 742: Postpartum Pain Management.
https://doi.org/10.1097/AOG.0000000000002683
Obstetrics and Gynecology;

May 21st, 2018 - Pain and fatigue are the most common problems reported by women in the early postpartum period. Pain can interfere with a woman's ability to care for herself and her infant. Untreated pain is associated with a risk of greater opioid use, postpartum depression, and development of persistent pain. Nonpharmacologic and pharmacologic therapies are important components of postpartum pain management....

A Brief Exposure-Based Treatment vs Cognitive Processing Therapy for Posttraumatic Stre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843538
JAMA Psychiatry; Sloan DM, Marx BP et. al.

Jan 18th, 2018 - Written exposure therapy (WET), a 5-session intervention, has been shown to efficaciously treat posttraumatic stress disorder (PTSD). However, this treatment has not yet been directly compared with a first-line PTSD treatment such as cognitive processing therapy (CPT). To determine if WET is noninferior to CPT in patients with PTSD. In this randomized clinical trial conducted at a Veterans Affa...

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838571
JAMA Psychiatry; Daly EJ, Singh JB et. al.

Dec 28th, 2017 - Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants. To assess the efficacy, safety, and dose-response of intranasal esketamine hydrochloride in patients with treatment-resistant depression (TRD). This phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study was conducted in multiple outpatient referral ce...

Insomnia tied to higher risk of heart disease and stroke
https://newsroom.heart.org/news/insomnia-tied-to-higher-risk-of-heart-disease-and-stroke

Aug 18th, 2019 - People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke, according to new research in the American Heart Association’s journal Circulation. Previous observational studies have found an association between insomnia, which affects up to 30% of the general population, and an increased risk of developing heart disease and stroke. These obse...

FDA warns consumers about the dangerous and potentially life threating side effects of Miracle Mineral Solution
https://www.fda.gov/news-events/press-announcements/fda-warns-consumers-about-dangerous-and-potentially-life-threating-side-effects-miracle-mineral

Aug 11th, 2019 - The U.S. Food and Drug Administration is warning consumers not to purchase or drink a product sold online as a medical treatment due to a recent rise in reported health issues. Since 2010, the FDA has warnedExternal Link Disclaimer consumers about the dangers of Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide (CD) Protocol, Water Purification Solution (WPS)...

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography
https://jamanetwork.com/journals/jamaneurology/fullarticle/2738356
JAMA Neurology; Mattsson, N. et. al.

Jul 16th, 2019 - Question Can a longitudinally valid in vivo β-amyloid staging system be constructed for Alzheimer disease? Findings In this multicenter longitudinal cohort study, a 4-level staging system using fluorine 18–labeled florbetapir positron emission tomography was defined using a combination of cerebrospinal fluid and positron emission tomography data. The β-amyloid stages had distinct associati...

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2737101
JAMA Network Open;

Jul 2nd, 2019 - Question Is androgen deprivation therapy exposure associated with dementia among elderly patients with prostate cancer? Findings In this cohort study of 154 089 elderly men with prostate cancer, androgen deprivation therapy exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years. Meaning Clinicians must carefully w...

FDA issues warnings to companies selling illegal, unapproved kratom drug products marketed for opioid cessation, pain treatment and other medical uses
https://www.fda.gov/news-events/press-announcements/fda-issues-warnings-companies-selling-illegal-unapproved-kratom-drug-products-marketed-opioid

Jun 24th, 2019 - The U.S. Food and Drug Administration issued warning letters to two marketers and distributors of kratom products – Cali Botanicals of Folsom, California, and Kratom NC of Wilmington, North Carolina – for illegally selling unapproved, misbranded kratom-containing drug products with unproven claims about their ability to treat or cure opioid addiction and withdrawal symptoms. The companies also ...

Statement on the FDA’s benefit-risk framework for evaluating opioid analgesics
https://www.fda.gov/news-events/press-announcements/statement-fdas-benefit-risk-framework-evaluating-opioid-analgesics

Jun 19th, 2019 - Addressing the crisis of opioid addiction is an issue of great concern for our nation and remains a top public health priority for the FDA. The agency continues to take new steps to confront this crisis, while also paying careful attention to the needs of patients in accessing appropriate pain management. Opioids present unique challenges: they have benefits when used as prescribed yet have ver...

Depression Following Acute Coronary Syndrome Events: Screening and Treatment Guidelines from the AAFP
https://www.aafp.org/afp/2019/0615/od2.html
American Family Physician;

Jun 14th, 2019 - Purpose: To review the evidence and provide clinical recommendations for the screening and treatment of depression in patients who have had a recent acute coronary syndrome event. Methods: This guideline is based on a systematic review of randomized controlled trials and observational studies from January 1, 2003, to August 15, 2017. It is an update to a previous systematic review published ...

Antidepressants plus benzodiazepines for adults with major depression
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001026.pub2/full
The Cochrane Database of Systematic Reviews; Ogawa, Y. et. al.

Jun 2nd, 2019 - Background Anxiety frequently coexists with depression and adding benzodiazepines to antidepressant treatment is common practice to treat people with major depression. However, more evidence is needed to determine whether this combined treatment is more effective and not any more harmful than antidepressants alone. It has been suggested that benzodiazepines may lose their efficacy with long‐te...

Statement on FDA’s request for information on requiring fixed-quantity blister packaging for certain opioid pain medicines to help decrease unnecessary exposure to opioids
https://www.fda.gov/news-events/press-announcements/statement-fdas-request-information-requiring-fixed-quantity-blister-packaging-certain-opioid-pain

May 29th, 2019 - The opioid tragedy has become one of the defining public health crises of modern times. As the rates of opioid addiction and overdose continue to grow, addressing the opioid crisis has taken on more urgency. For the past few years, the U.S. Food and Drug Administration has been focusing on decreasing unnecessary exposure to prescription opioids as a way to prevent new addiction; supporting the ...

Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression
https://www.allergan.com/news/news/thomson-reuters/allergan-and-gedeon-richter-receive-u-s-fda-approv.aspx

May 27th, 2019 - Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for VRAYLAR® (cariprazine) for expanded use to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults. VRAYLAR is also approved in the U.S. to treat manic or mixed episodes associated with ...

Bipolar disorder and risk of Parkinson disease: A nationwide longitudinal study.
https://doi.org/10.1212/WNL.0000000000007649
Neurology Huang MH, Cheng CM et. al.

May 23rd, 2019 - To evaluate the risk of Parkinson disease (PD) among patients with bipolar disorder (BD). Using the Taiwan National Health Insurance Research Database, we examined 56,340 patients with BD and 225,360 age- and sex-matched controls between 2001 and 2009 and followed them to the end of 2011. Individuals who developed PD during the follow-up period were identified. Patients with BD had a higher inc...

Association Between Parental Medical Claims for Opioid Prescriptions and Risk of Suicid...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537764
JAMA Psychiatry; Brent DA, Hur K et. al.

May 22nd, 2019 - The rate of youth suicide has increased over the past 15 years in the United States as has the rate of death due to opioid overdose in adults of parental age. To explore the possible connection between parental use of prescription opioids and the increasing rate of youth suicide. A pharmacoepidemiologic study was conducted from January 1, 2010, to December 31, 2016, linking medical claims for p...

ATS Conference 2019 - American Thoracic Society
http://conference.thoracic.org/

May 14th, 2019 - The American Thoracic Society improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders.

Prescription Drug Use in the United States, 2015–2016
https://www.cdc.gov/nchs/products/databriefs/db334.htm
Martin. C., et al

May 8th, 2019 - In 2015–2016, 45.8% of the U.S. population used prescription drugs in the past 30 days. Prescription drug use increased with age, from 18.0% of children under age 12 years to 85.0% of adults aged 60 and over. Prescription drug use was highest among non-Hispanic white persons followed by non-Hispanic black persons, and lowest among non-Hispanic Asian and Hispanic persons. The most commonly us...

FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines
https://www.fda.gov/news-events/press-announcements/fda-requires-stronger-warnings-about-rare-serious-incidents-related-certain-prescription-insomnia

Apr 29th, 2019 - The U.S. Food and Drug Administration today announced the agency is requiring a new boxed warning – the agency’s most prominent warning – on certain prescription insomnia drugs to better ensure patients and their health care professionals have the information they need when considering use of these medicines. The boxed warning follows several reports of rare, but serious injuries and deaths res...

National Institute on Alcohol Abuse and Alcoholism - What Is A Standard Drink?
https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/what-standard-drink

Apr 28th, 2019 - Many people are surprised to learn what counts as a drink. The amount of liquid in your glass, can, or bottle does not necessarily match up to how much alcohol is actually in your drink. Different types of beer, wine, or malt liquor can have very different amounts of alcohol content. For example, many light beers have almost as much alcohol as regular beer – about 85% as much.